Type 1 Diabetes Preclinical Testing Program
Bridging Discovery to Therapy


Printed version of brochure (PDF, 66 kb)
NIDDK’s Type 1 Diabetes Preclinical Support programs are designed to remove the most common barriers impeding progress from laboratory discoveries to new therapies for T1D and its complications.

T1D-Preclinical Testing Program

The Type 1 Diabetes Preclinical Testing Program (T1D-PTP) provides investigators with access to resources to support expanded preclinical efficacy testing of promising new therapeutics.

T1D Prevention & Reversal (NOT-DK-09-006)

Services:
  • Protocol development to extend preclinical data in support of agents that may prevent, slow or reverse Type 1 Diabetes
  • Facilities and expertise to test potential therapeutics in established rodent models of diabetes
  • Promising agents that may be tested in both rodents and humans are particularly encouraged

T1D Complications (NOT- DK-09-009)

Services:
  • Protocol development to extend preclinical data in support of agents that may prevent, slow or reverse complications of T1D
  • Facilities and expertise to test potential therapeutics in established rodent models of diabetic complications
  • Promising agents that may be tested in both rodents and humans are particularly encouraged
For more information about services and access please visit http://t1diabetes.nih.gov/T1D-PTP/

T1D-RAID

T1D-RAID provides investigators with access to resources to support pre-clinical development of promising therapeutics for T1D.

Type 1 Diabetes Rapid Access to Intervention Development

Services:
  • Dose optimization
  • Pharmacology
  • Bulk substance (GMP & non-GMP)
  • Scale-up
  • Formulation
  • Toxicology
Advice:
  • Planning Clinical Trials
  • Regulatory Affairs
  • IND filing
For more information please visit http://t1diabetes.nih.gov/T1D-RAID/

Service Requests

Eligibility

The following types of organizations are eligible to request program resources:
  • Academic institutions
  • Non-profit research institutions
  • Biotechnology and pharmaceutical companies
  • U.S. and non-U.S. entities

Request Process

  • T1D-RAID receives requests twice per year (April 1 and November 1). A letter of intent is encouraged one month prior to submission of a request. For details: http://t1diabetes.nih.gov/T1D-RAID/
  • T1D-PTP will receive requests at any time throughout the year. A letter of intent is encouraged one month prior to submission of a request. For details: http://t1diabetes.nih.gov/T1D-PTP/

What the Type 1 Diabetes Preclinical Testing Program is not:

  • T1D-RAID and T1D-PTP are not intended to be a pipeline for materials for NIH-held INDs. It is assumed that most of the products studied will be advanced clinically under investigator -held INDs within the originating (or collaborating) institution.
  • Acceptance into either program is not an unconditional commitment to develop a particular compound for clinical use. Development will proceed sequentially with pre-defined milestones.
  • These programs do not provide grants or awards to investigator laboratories. The great majority of resources committed will be directed to existing preclinical support contracts held solely by the NIDDK or jointly by NIDDK in partnership with NCI.
  • T1D-RAID is not intended to support provision of materials for larger Phase II and III clinical trials.
Last Updated: 05/12/2009

General Inquiries may be addressed to:
Office of Communications and Public Liaison
NIDDK, NIH
Building 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560 USA
For information about NIDDK programs: 301.496.3583